LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML-Reference-Cited by-同舟云学术

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Published:2018-04-12 Issue:15 Volume:131 Page:1730-1742
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cusan Monica¹²,Cai Sheng F.¹^ORCID,Mohammad Helai P.³,Krivtsov Andrei¹⁴,Chramiec Alan¹,Loizou Evangelia¹,Witkin Matthew D.¹,Smitheman Kimberly N.³,Tenen Daniel G.⁵,Ye Min⁵,Will Britta⁶,Steidl Ulrich⁶,Kruger Ryan G.³,Levine Ross L.¹,Rienhoff Hugh Y.⁷,Koche Richard P.¹,Armstrong Scott A.¹⁴

Affiliation:

1. Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY;

2. University Hospital, Ludwig Maximilian University Munich, Munich, Germany;

3. GlaxoSmithKline, Newark, NJ;

4. Department of Pediatric Oncology, Dana-Farber Cancer Institute, and

5. Harvard Stem Cell Institute, Harvard Medical School, Boston, MA;

6. Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY; and

7. Imago Biosciences, Inc., San Francisco, CA

Abstract

Key Points LSD1 inhibition induces a global increase in chromatin accessibility, whereas DOT1L inhibition induces global decreases in accessibility. Perturbation of PU.1 and C/EBPα expression renders AML cells more resistant to LSD1 inhibition.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/15/1730/1405775/blood807024.pdf

Reference38 articles.

1. Recurring mutations found by sequencing an acute myeloid leukemia genome;Mardis;N Engl J Med,2009

2. Genomic classification and prognosis in acute myeloid leukemia;Papaemmanuil;N Engl J Med,2016

3. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains;Shi;Nat Biotechnol,2015

4. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L;Bernt;Cancer Cell,2011

5. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells;Harris;Cancer Cell,2012

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy;Journal of Medicinal Chemistry;2024-01-12

2. RNA m6A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression;Genes & Diseases;2024-01

3. Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD;Journal of Lipid Research;2024-01

4. Ginsenoside Rd Induces Differentiation of Myeloid Leukemia Cells via Regulating ERK/GSK-3β Signaling Pathway;Chinese Journal of Integrative Medicine;2023-12-12

5. LSD1 in drug discovery: From biological function to clinical application;Medicinal Research Reviews;2023-11-28